Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Horwitz

Showing results (591-600 of 717) with videos related to

Pageof 72
Sort By:
Blood Advances|February 9, 2021
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell ProjectAndrei Shustov, Maria Elena Cabrera, Monica Civallero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Hematological Oncology|September 9, 2022
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma projectCarlos Chiattone, Monica Civallero, Thais Fischer, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2019
Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical TrialsChristopher L Hallemeier, Peixin Zhang, Thomas M Pisansky, et al.
Blood Advances|April 26, 2022
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2Kerry J Savage, Steven M Horwitz, Ranjana Advani, et al.
European Urology|May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 TrialOliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Pageof 72

Showing results (591-600 of 717) with videos related to

Sort By:
Pageof 72
Blood Advances|February 9, 2021
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell ProjectAndrei Shustov, Maria Elena Cabrera, Monica Civallero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Hematological Oncology|September 9, 2022
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma projectCarlos Chiattone, Monica Civallero, Thais Fischer, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2019
Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical TrialsChristopher L Hallemeier, Peixin Zhang, Thomas M Pisansky, et al.
Blood Advances|April 26, 2022
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2Kerry J Savage, Steven M Horwitz, Ranjana Advani, et al.
European Urology|May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 TrialOliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Pageof 72